MET and non-small cell lung carcinoma: Acquired NSCLC resistance to TKIs has also been associated to overexpression and activation of other receptor tyrosine kinases (RTKs) including HER3, AXL or MET [22–26], to modulation of Fas receptor and NF-kB signaling pathways [27] and to epithelial to mesenchymal transition (EMT) [28–30].